Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes.

Slides:



Advertisements
Similar presentations
William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN For The ACCORD Study Group.
Advertisements

11/2/ Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.
Valsartan Antihypertensive Long-Term Use Evaluation Results
Main Trial Design and Trial Status
Henry C. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.
Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Rury R. Holman, MB, ChB, FRCP Professor of Diabetic Medicine Director, Diabetes.
Overview of the CVD Risk Reduction Demonstration Project Kelly Acton, MD, MPH, FACP IHS Division of Diabetes Treatment & Prevention.
Henry N. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.
Are We Nearing the Limits of Office-Based CV Prevention? Thomas G. Allison, PhD, MPH.
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
on behalf of the INVEST Investigators
Blood Pressure Control By Randomized Drug Group In ALLHAT William C. Cushman, Charles E. Ford, Paula T. Einhorn, Jackson T. Wright, Jr., Richard A. Preston,
Casablanca, le 30 Avril 2011 MEDITERANEAN GROUP FOR STUDY DIABETES.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
Morbidity and Mortality in Contemporary CAD Patients With Hypertension Treated With Either a Verapamil/Trandolapril or Beta-Blocker/Diuretic Strategy (INVEST):
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN For The ACCORD Study Group.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Tailoring Intervention – Effectively Targeting the High-risk Population Cardiovascular Event Reduction in the Higher-Risk Primary Prevention Population.
1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Prognostic Value of B-Type Natriuretic Peptides in Patients with Stable Coronary Artery Disease The PEACE trial Omland T, et al. JACC 2007;50:
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
Clinical Outcomes with Newer Antihyperglycemic Agents
Antonio Coca, MD, PhD, FRCP, FESC
William C. Cushman, MD Chief, Preventive Medicine Section,
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Blood Pressure and Lipid Trials: Rationale, Importance and Design
What should the Systolic BP treatment goal be in patients with CKD?
Clinical Outcomes with Newer Antihyperglycemic Agents
Nephrology Journal Club The SPRINT Trial Parker Gregg
The ACCORD Trial: Review of Design and Results
ACCORD Microvascular Outcomes
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
The SPRINT Research Group
ACCORD Design and Baseline Characteristics
Hypertension in the Post SPRINT era
Hypertension JNC VIII Guidelines.
Health and Human Services National Heart, Lung, and Blood Institute
Vanguard Phase Results for the Blood Pressure Component
ALLHAT ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status.
HOPE: Heart Outcomes Prevention Evaluation study
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
The Anglo Scandinavian Cardiac Outcomes Trial
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
Blood Pressure Measurement in SPRINT
Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.
Systolic Blood Pressure Intervention Trial (SPRINT)
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
The following slides highlight a report on a presentation at the Late-breaking Trials Session and a Satellite Symposium of the American Heart Association.
The Hypertension in the Very Elderly Trial (HYVET)
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Health and Human Services National Heart, Lung, and Blood Institute
Systolic Blood Pressure Intervention Trial Goals and Rationale
Diabetes Journal Club March 17, 2011
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
Table of Contents Why Do We Treat Hypertension? Recommendation 5
The following slides highlight a report by Dr
Presentation transcript:

Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN For The ACCORD Study Group

ACCORD Sponsor, Collaborators and Contributors Sponsor: The National Heart, Lung, and Blood Institute (NHLBI) Collaboration & support National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) National Eye Institute (NEI) National Institute on Aging (NIA) Centers for Disease Control and Prevention (CDC) Contributions Abbott Laboratories (and Fournier Laboratories) AstraZeneca Pharmaceuticals LP Sanofi-Aventis U.S GlaxoSmithKline Pharmaceuticals King Pharmaceuticals, Inc. MediSense Products (division of Abbott Laboratories) Merck & Company, Inc. Closer Healthcare Inc. Novartis Pharmaceuticals. Inc. Novo Nordisk Pharmaceuticals., Inc. Omron Healthcare, Inc. Amylin Pharmaceuticals, Inc. Takeda Pharmaceuticals Inc

ACCORD Study Design Randomized multi-center clinical trial Conducted in 77 clinical sites in North America (U.S. and Canada) Designed to independently test three medical strategies to reduce CVD in diabetic patients BP question: does a therapeutic strategy targeting systolic blood pressure (SBP) <120 mmHg reduce CVD events compared to a strategy targeting SBP <140 mmHg in patients with type 2 diabetes at high risk for CVD events?

ACCORD Double 2 x 2 Factorial Design Lipid BP Placebo Fibrate Intensive Standard Intensive Glycemic Control 1383 1374 1178 1193 5128 Standard Glycemic Control 1370 1391 1184 1178 5123 2753 2765 2362 2371 10,251 5518 4733* * 94% power for 20% reduction in event rate, assuming standard group rate of 4% / yr and 5.6 yrs follow-up

ACCORD BP Trial Eligibility Stable Type 2 Diabetes >3 months HbA1c 7.5% to 11% (or <9% if on more meds) High CVD risk = clinical or subclinical disease or ≥2 risk factors Age (limited to <80 years after Vanguard) ≥ 40 yrs with history of clinical CVD (secondary prevention) ≥ 55 yrs otherwise Systolic blood pressure 130 to 160 mm Hg (if on 0-3 meds) 161 to 170 mm Hg (if on 0-2 meds) 171 to 180 mm Hg (if on 0-1 meds) Urine protein <1.0 gm/24 hours or equivalent Serum Creatinine ≤1.5 mg/dl

ACCORD BP Protocol Many drugs/combinations provided to achieve goal BP according to randomized assignment. Intensive Intervention: 2-drug therapy initiated: thiazide-type diuretic + ACEI, ARB, or b-blocker. Drugs added and/or titrated at each visit to achieve SBP <120 mm Hg. At periodic “milepost” visits: addition of another drug “required” if not at goal. Standard Intervention: Intensify therapy if SBP ≥160 mm Hg @ 1 visit or ≥140 mm Hg @ 2 consecutive visits Down-titration if SBP <130 mm Hg @ 1 visit or <135 mm Hg @ 2 consecutive visits

Baseline Characteristics Mean or % Age (yrs) 62 Blood Pressure (mm Hg) 139/76 Women % 48 On Antihypertensive % 87 2° prevention % 34 Creatinine (mg/dL) 0.9 Race / Ethnicity eGFR (mL/min/1.73m2) 92 White % 61 DM Duration (yrs)* 10 Black % 24 A1C (%) 8.3 Hispanic % 7 BMI (kg/m2) 32 * Median value 7

Systolic Pressures (mean + 95% CI) Mean # Meds Intensive: 3.2 3.4 3.5 3.4 Standard: 1.9 2.1 2.2 2.3 Average after 1st year: 133.5 Standard vs. 119.3 Intensive, Delta = 14.2 8

Medications Prescribed (12 Month Visit)

Adverse Events Intensive N (%) Standard P Serious AE 77 (3.3) 30 (1.3) <0.0001 Hypotension 17 (0.7) 1 (0.04) Syncope 12 (0.5) 5 (0.2) 0.10 Bradycardia or Arrhythmia 3 (0.1) 0.02 Hyperkalemia 9 (0.4) 0.01 Renal Failure 0.12 eGFR ever <30 mL/min/1.73m2 99 (4.2) 52 (2.2) <0.001 Any Dialysis or ESRD 59 (2.5) 58 (2.4) 0.93 Dizziness on Standing† 217 (44) 188 (40) 0.36 † Symptom experienced over past 30 days from HRQL sample of N=969 participants assessed at 12, 36, and 48 months post-randomization

Clinical Parameters assessed at last clinic visit Intensive Standard P Potassium (mean mg/dl) 4.3 4.4 0.17 Serum Creatinine 1.1 1.0 <0.0001 Estimated GFR (mean mL/min/1.73m2) 74.8 80.6 Urinary Alb/Cr (median mg/g) 12.6 14.9 Macroalbuminuria (%) 6.6 8.7 0.009

Primary & Secondary Outcomes Intensive Events (%/yr) Standard HR (95% CI) P Primary 208 (1.87) 237 (2.09) 0.88 (0.73-1.06) 0.20 Total Mortality 150 (1.28) 144 (1.19) 1.07 (0.85-1.35) 0.55 Cardiovascular Deaths 60 (0.52) 58 (0.49) 1.06 (0.74-1.52) 0.74 Nonfatal MI 126 (1.13) 146 (1.28) 0.87 (0.68-1.10) 0.25 Nonfatal Stroke 34 (0.30) 55 (0.47) 0.63 (0.41-0.96) 0.03 Total Stroke 36 (0.32) 62 (0.53) 0.59 (0.39-0.89) 0.01 Also examined Fatal/Nonfatal HF (HR=0.94, p=0.67), a composite of fatal coronary events, nonfatal MI and unstable angina (HR=0.94, p=0.50) and a composite of the primary outcome, revascularization and unstable angina (HR=0.95, p=0.40)

Primary Outcome HR = 0.88 95% CI (0.73-1.06) Nonfatal MI, Nonfatal Stroke or CVD Death HR = 0.88 95% CI (0.73-1.06)

Nonfatal Stroke Total Stroke HR = 0.63 HR = 0.59 95% CI (0.41-0.96)

Stroke Results Intensive BP management reduced the rate of two closely correlated secondary end points: total stroke (p=0.01) and nonfatal stroke (p=0.03). Assuming that this finding was real, the number needed to treat to the lower SBP level to prevent one stroke over 5 years was 89. These effects would be consistent with meta-analyses summarizing the impact of a 10 mm Hg reduction in SBP on strokes from observational studies (relative risk=0.64) and drug treatment trials (relative risk=0.59).

Primary Outcome by Pre-defined Subgroups Also examined DBP tertiles (p=0.70) and number of screening meds (p=0.44)

Conclusions The ACCORD BP trial evaluated the effect of targeting a SBP goal of 120 mm Hg, compared to a goal of 140 mm Hg, in patients with type 2 diabetes at increased cardiovascular risk. The results provide no conclusive evidence that the intensive BP control strategy reduces the rate of a composite of major CVD events in such patients.

Published online March 14, 2010